SORD Deficiency

What you need to know

Applied Therapeutics is a clinical-stage biopharmaceutical company conducting an international phase III randomized interventional trial for patients with Sorbitol Dehydrogenase (SORD) Deficiency called INSPIRE. This trial is designed to investigate the ability of AT-007 versus placebo to reduce toxic sorbitol levels and to evaluate the effect of AT-007 on improving disease symptoms over a longer period. HNF has been instrumental in helping to facilitate and accelerate the approval of their clinical lead product AT-007, an Aldose Reductase Inhibitor (ARI) currently in clinical trials.

Genetic Testing for SORD

Learn how to get tested!

Learn how to get tested for SORD Deficiency by booking a call!

What is Sorbitol Dehydrogenase (SORD) Deficiency?

Sorbitol Dehydrogenase (SORD) Deficiency is a recently discovered rare, genetic metabolic disease. 

People with SORD Deficiency are missing a key enzyme needed to metabolize a sugar called sorbitol.

Before the discovery of the SORD gene, patients with SORD Deficiency were diagnosed based on their symptoms as having Charcot-Marie-Tooth disease (CMT2) or distal hereditary motor neuropathy (dHMN). The recent discovery that disease symptoms in CMT2 and dHMN can be caused by genetic mutations in the SORD enzyme, now gives people living with SORD Deficiency, and their physicians, greater understanding of their specific disease.  It also provides the opportunity to participate in a clinical trial of an investigational new treatment targeting the underlying cause of SORD Deficiency.

How many people have SORD Deficiency?

SORD Deficiency is a rare disease that impacts 1 in every 100,000 people.  In the US, it is estimated that there are only 3,300 individuals living with the disease.

SORD Deficiency is a form of hereditary neuropathy, which means that this disease was passed down from both parents’ genes.  Not all people with SORD Deficiency have a family history of hereditary neuropathy.

What happens in the body of someone living with SORD Deficiency?

Glucose is a simple sugar that the body converts into fructose for energy.  One of the ways the body breaks down glucose is through a two-step metabolic pathway.

In this metabolic pathway, two enzymes work to process glucose and then sorbitol.

  1. In the first step, the enzyme Aldose Reductase metabolizes glucose into sorbitol
  2. In the second step, the enzyme Sorbitol Dehydrogenase (SORD) converts sorbitol into fructose

Inspire Clinical Trial - PDF

An introduction to SORD Deficiency - PDF

Learn more on this topic

Latest News and Related Blog Posts

2024 CMT Roadshow Coming to a City Near You?

2024 CMT Roadshow Coming to a City Near You?

Do you want to make a difference in CMT research? HNF is looking for patients with a confirmed CMT diagnosis to participate in the CMT Biobank